Coming Soon: Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

News
Video

Expert Matthew Lunning, DO, FACP, shares his excitement for an upcoming case-based peer perspectives program wherein he reviews the diagnosis and management of a patient with DLBCL, considering evolving treatment paradigms and updated clinical data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      1 expert in this video
      Treatment Implementation and Long-Term Considerations in BPDCN
      Academic Perspectives on the Evolving Treatment Landscape in MPNs
      Academic Perspectives on the Evolving Treatment Landscape in MPNs
      1 expert in this video
      Adverse Events Monitoring and Management in BPDCN Treatment
      1 expert in this video
      Academic Perspectives on Treatment Decisions for BPDCN
      Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
      Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
      Advances in MPN Management: Insights From MANIFEST-2 and Beyond
      Advances in MPN Management: Insights From MANIFEST-2 and Beyond
      Ongoing studies of Ra-223–based combinations
      Ongoing studies of Ra-223–based combinations
      1 expert in this video
      Academic Perspectives on Systemic Therapy for Advanced uHCC
      Ongoing studies of Ra- 223–based combinations
      Ongoing studies of Ra- 223–based combinations
      Protecting bone health for patients receiving Ra-223 + ARPI combination
      Protecting bone health for patients receiving Ra-223 + ARPI combination
      Related Content
      Jacobson Discusses Second and Third-Line Options for DLBCL

      Jacobson Discusses Second and Third-Line Options for DLBCL

      Targeted Oncology Staff
      April 19th 2025
      Article

      During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

      Read More

      The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

      The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

      Nichole Tucker
      June 15th 2022
      Podcast

      In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

      Listen

      Odronextamab Shows Efficacy in DLBCL Post CAR T-Cell Therapy

      Odronextamab Shows Efficacy in DLBCL Post CAR T-Cell Therapy

      Jordyn Sava
      March 10th 2025
      Article

      Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean for oncologists.

      Read More

      Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

      Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

      Targeted Oncology Staff
      March 6th 2025
      Article

      During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary refractory or early relapsed DBLCL since the introduction of CAR T-cell therapy.

      Read More

      CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL

      CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL

      Targeted Oncology Staff
      February 20th 2025
      Article

      During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first article of a 2-part series.

      Read More

      Zamto-Cel Shows Durable Responses in Relapsed/Refractory DLBCL

      Zamto-Cel Shows Durable Responses in Relapsed/Refractory DLBCL

      Chris Ryan
      February 14th 2025
      Article

      Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

      Read More